Peripheral Neuropathies
Neuropathies associated with cytomegalovirus infection
Nov. 16, 2024
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Clinical evaluation of peripheral neuropathies …
- Updated 08.19.2023
- Released 05.12.1999
- Expires For CME 08.19.2026
Clinical evaluation of peripheral neuropathies
Introduction
Overview
Peripheral neuropathy is responsible for significant disability worldwide. However, a comprehensive diagnostic evaluation of this common condition is cumbersome and costly. A methodical approach is essential for proper localization and characterization of neuropathy and to develop targeted diagnostic testing. In this article, the authors review the clinical phenotype and classification of neuropathy and appropriate diagnostic testing.
Key points
|
• Detailed history, including onset and progression of symptoms, the pattern of involvement, social history, family history, medical history, surgical history, review of systems, and review of medications and supplements can help characterize the type of neuropathy and minimize unnecessary testing. | |
|
• A detailed neurologic examination, including motor system, sensory testing, tendon reflexes, and gait examination, is essential to understand the pattern of involvement. | |
|
• Anatomic classification of neuropathy includes (1) fiber type (motor vs. sensory, large vs. small, somatic vs. autonomic), (2) component of fiber affected (axon vs. myelin), and (3) distribution of nerves affected (length-dependent, length-independent, focal, and multifocal). | |
|
• Initial screening for distal symmetric neuropathy usually includes fasting blood glucose, comprehensive metabolic panel, liver function test, complete blood count and differential, serum vitamin B12, and serum immunofixation electrophoresis (IFE). If fasting blood glucose is normal, consider a 2-hour oral glucose tolerance test. | |
|
• Nerve conduction studies and needle electromyography (EMG) are valuable in evaluating large fiber polyneuropathy diagnosis. They aid in distinguishing axonal and demyelinating components, assessing neuropathy severity, following progression or response to treatment, and helping exclude mimics of polyneuropathy such as myopathy, neuronopathy, plexopathy, or polyradiculopathy. | |
|
• Skin biopsy that assesses epidermal nerve fiber density and sweat gland nerve fiber density is helpful for small fiber neuropathy diagnosis. | |
|
• Nerve biopsy is most useful in acute/subacute, asymmetric, multifocal, and progressive neuropathy. It should not be performed in routine cases. | |
|
• The majority of neuropathies, except some autoimmune neuropathies, are not curable, and treatment is targeted at offering symptomatic relief. Acquired demyelinating polyneuropathies, although rare, are often treatment responsive. |
Historical note and terminology
Peripheral neuropathy refers to any acquired or hereditary condition with damaged peripheral nerves. The associated motor and sensory symptoms can be disabling in some patients, leading to falls, limited ambulation and daily activities, and impaired quality of life. The prevalence of polyneuropathy is 5.5% based on the Rotterdam Study, which increases from up to 25.4% to 31.2% among patients over the age of 70, even in the absence of diabetes (33; 37). Given the wide variety of peripheral neuropathies, and an even higher number of potential etiologies, a structured diagnostic approach and management plan may potentially improve patient care (37; 66).
Clinical manifestations
Presentation and course
The clinical manifestations of neuropathy depend on the type and distribution of affected nerve modalities, the degree of axonal or myelin damage, and the course of the disease. Demyelinating neuropathies primarily affect the myelin sheaths, whereas axonal neuropathies target the peripheral nerve axons. When motor nerves are affected, weakness and muscle atrophy occur. Damage to sensory nerves can cause numbness, paresthesia, dysesthesia, pain, and sensory ataxia. Involvement of small myelinated and unmyelinated sensory fibers typically results in impaired pin prick and temperature sensation, numbness, and painful burning, cold, or stinging paresthesias. Large diameter sensory fiber involvement manifests as loss of vibration and position sensation, sensory ataxia, and numbness or paresthesias. Autonomic dysfunction can result in postural hypotension, impotence, gastrointestinal and genitourinary dysfunction, abnormal sweating, and hair loss. Deep tendon reflexes are frequently diminished or absent, particularly in demyelinating neuropathies. Because most nerve trunks have a mixture of fiber types, damage to the peripheral nerves often affects more than one of these modalities (20).
Peripheral neuropathy can be divided into several categories:
|
• Polyneuropathy is distinct from mononeuropathy as it usually refers to diffuse involvement of the peripheral nerves and is usually first noted distally in the feet and later in the lower legs and hands. | |
|
• Mononeuropathy or radiculopathy refers to involvement of a single nerve or nerve root, respectively. | |
|
• Mononeuropathy (mononeuritis) multiplex signifies focal involvement of two or more nerves in a multifocal pattern. The term “neuritis” is usually restricted to inflammatory conditions, such as vasculitic neuropathy. | |
|
• Neuronopathy refers to primary involvement of the nerve cell body, rather than its axon; ganglioneuritis refers to inflammatory involvement of the nerve cell bodies, usually in the sensory or autonomic ganglia. | |
|
• Plexopathy or plexitis refers to involvement of brachial or lumbosacral plexus. |
Neuropathies are classified according to the clinical syndrome, pathological features, associated underlying condition, or other specific etiology. A classification of peripheral neuropathies is shown in the differential diagnosis section (Tables 1 and 2).
Approach to the patient with suspected peripheral neuropathy
History. A detailed history can help in identifying the modalities of nerve involvement (motor/sensory/sensorimotor/autonomic), identifying the pattern of involvement (symmetric, asymmetric, length dependent or not), and understanding the temporal course. Patients often minimize or neglect to notice “negative” symptoms (loss of function), but frequently complain of “positive” symptoms (altered function) listed in Table 3. Negative symptoms, therefore, should be specifically elicited. Weakness often impairs specific function; proximal or distal weakness can be deduced from changes in daily abilities. Difficulties in climbing stairs and getting up from a low seated position indicate proximal weakness, whereas foot slapping is a common complaint for distal weakness of the lower extremities. Similarly, combing hair, brushing teeth, or reaching high shelves can become difficult with proximal upper extremity weakness, and using utensils and other fine motor movements can be affected with distal upper extremity weakness. Heaviness, numbness, and balance difficulty--especially in the dark--are common descriptions with large fiber neuropathy. Paresthesia and shooting or stabbing pain are common small fiber symptoms and may be more prominent when walking; comfortable shoes are usually adopted by the patient. Patients may note altered temperature perception, especially differences in water temperature sense with different body areas or misperception of hot for cold. Symptoms tend to be worse at night when other sensory distractions are less. Cold and dry distal extremities are frequently noted. Autonomic symptoms (commonly present in diabetic and amyloid neuropathies) are often underreported by patients, and associated sexual dysfunctions can be perceived as embarrassing, unless directly inquired about (68; 20; 09; 27). Erectile dysfunction can be the first presentation of diabetic autonomic neuropathy and may affect up to 75% men with diabetes (45).
Not all symptoms of distal numbness, tingling, pain, and weakness are caused by peripheral nerve dysfunction; a central nervous system process or even a somatoform disorder may be responsible. A detailed history, including general medical history with current and prior illnesses, current and prior medications, and other medical and alternative therapies, can improve diagnostic accuracy when combined with the knowledge of functional neuroanatomy and nerve physiology.
Diabetes mellitus accounts for 30% to 50% of cases of distal sensory polyneuropathy (75; 32). If questioned, patients acknowledge a prior “high sugar” or prediabetes but may not admit to frank diabetes. Peripheral neuropathy has been reported as the presenting symptom of impaired glucose tolerance (59; 23). Patients with systemic rheumatological diseases are also vulnerable to peripheral neuropathy (31). Many medications, especially chemotherapeutic agents, may cause neuropathy (56; 70; 50). A long but partial list of neuropathy causes is presented in Table 1. Other pertinent social, recreational, and occupational exposures are important but are less frequently involved, except for alcohol. A more general review of systems is useful to reveal signs suggestive of underlying conditions, especially systemic signs of malignancy, collagen vascular disease, infection, or vasculitis. Gastrointestinal symptoms could provide clues to inflammatory bowel disease or celiac disease (15). Some hereditary disorders are asymptomatic into adulthood so a thorough family history and age of onset is essential. Inquiring about hereditary neuropathy or Charcot-Marie-Tooth disease often fails to prompt recognition, so more direct questions such as: “does anyone in your family have high arched feet, or hammer/curled up toes?” are more probative. Childhood difficulty with running or other sporting activities may be helpful to establish a hereditary condition. Other questions include: “Do you have difficulty walking on heels or rising from a kneeling position?”, “Is there associated wasting of the hands or feet?”, and “Are there any hand, foot, or spinal deformities?” Patients should be questioned about HIV risk factors, recent travel. Dietary habits can help in assessing nutritional dysfunction, including supplementation-related vitamin B6 toxicity (46). In addition, inquiring about factors for the metabolic syndrome is important as it predisposes patients beyond glucose dysmetabolism to painful neuropathy (44).
Physical examination. The general examination should include a detailed assessment of motor, sensory, and autonomic systems, including reflexes, gait, and cranial nerves.
Muscles should be inspected for the presence of atrophy (which typically begins in distal muscles), fasciculations, and myokymia (worm-like movement under the skin). A thorough manual muscle strength testing should be performed. Functional assessments (such as having patients walk on their toes and heels or hop on one leg at a time) may detect more subtle weakness. Orthopedic signs, such as high-arched feet, fallen arches, and hammer toes, suggest a longstanding condition. Prominent motor deficits (comparable to or greater than sensory deficits) may suggest an underlying demyelinating disorder, such as chronic inflammatory demyelinating polyneuropathy (CIDP), or a hereditary neuropathy. CIDP patients may have proximal muscle weakness (05; 20).
The sensory examination can be challenging, and patient cooperation is important. Both small and large sensory fiber modalities should be tested, most commonly pin sensation for small fiber function and vibration and joint position for large fiber function. Cold and warm sensation may also be tested. Pseudoathetosis may be present with significant large fiber impairment. The Romberg sign can be helpful in assessing sensory ataxia. The pattern of sensory loss should be ascertained; occasionally a sensory level is found that diverts the localization (05; 20; 09).
Deep tendon reflexes can be diminished in a length-dependent manner, and often the ankle jerk can be absent in the more common phenotype of distal symmetric neuropathy. Elicitation of deep tendon reflexes may require reinforcement methods if initially absent (eg, Jendrassik maneuver—pulling apart interlocked hands). A search for diffuse loss of reflex or hyporeflexia may suggest demyelinating neuropathy or hereditary neuropathy. Asymmetric reflex can be seen in superimposed mononeuropathy or a radiculopathy. Concomitant central nervous system problems (such as myelopathy, cervical stenosis, subacute combined degeneration from vitamin B12 deficiency) may complicate the findings of reflex exam (20).
Cranial nerve assessment can provide further diagnostic clues. Optic atrophy can be present in inherited neuropathies with central and peripheral demyelination. Absent pupillary light reflex and anisocoria may imply autonomic dysfunction. Ophthalmoparesis can be present in certain variants of Guillain-Barre syndrome or mitochondrial cytopathies (05).
A search for autonomic dysfunction should include orthostatic blood pressure measures, a thorough inspection of the skin and orthopedic integrity, palpation of distal pulses, palpation of nerves, and a focused systemic examination that may expose the presence of underlying systemic disease. A fall of greater than 20 mmHg of systolic blood pressure or greater than 10 mmHg of diastolic blood pressure recorded at least 3 minutes after standing following 5 minutes of supine rest is the definition of orthostatic hypotension. A sustained heart rate increase of greater than 40 beats per minute within 10 minutes of standing for individuals aged 12 to 19 years, and a sustained heart rate increase of greater than 30 beats per minute in individuals aged greater than 20, in the absence of orthostatic hypotension, is the definition of postural tachycardia syndrome, or POTS (28; 27). It is important to note that both orthostatic hypotension and POTS may occur in the absence of neuropathy or may be related to a concomitant neuropathy as a dysautonomic feature (27). Common distal skin changes suggestive of small fiber and autonomic dysfunction include skin thinning and scaling, hair loss, coldness, and dryness.
Prognosis and complications
Prognosis and complications depend on the type and severity of the neuropathy.
Clinical vignette
Vignette 1. A 56-year-old woman with hypertension, hyperlipidemia, and prediabetes presented with painful paresthesia in her lower extremities for 3 years. It started in her feet but progressed up to her ankle in the last 8 to 12 months, and the intensity was much more severe now. She denied having any other focal neurologic symptoms. Her motor strength was intact. Sensation to monofilament was reduced, and she reported a tingling sensation when testing pinprick sensation. Vibration and proprioception were intact. Her blood pressure was 144/84 despite being on an antihypertensive. Her body mass index was 33 kg/m2. Her most recent HDL level was 42 mg/dL, and her triglyceride level was 190 mg/dL. Fasting blood glucose was 130 mg/dL. The rest of the basic work-up, including vitamin B12 level, SPEP, and immunofixation, was normal. Her presentation was consistent with cryptogenic sensory peripheral neuropathy likely from metabolic syndrome (she fit the diagnostic criteria of metabolic syndrome as defined by the International Diabetes Federation). Apart from symptomatic treatment, exercise-based lifestyle modification was strongly recommended (44)
Vignette 2. A 29-year-old man without any significant past medical history presented with progressive painful lower extremity paresthesia and difficulty in ambulation for the last 3 to 4 weeks. He did not have any other focal neurologic symptoms. His exam reflected intact cranial nerves, mild distal motor weakness in the lower extremities, and significant sensory loss to all modalities in the lower extremities. His nerve conduction studies showed severe sensory motor axonal neuropathy. MRI lumbar spine did not show any nerve root thickening or contrast enhancement. CSF analysis did not show any albuminocytological dissociation. On further questioning, he admitted to having been following a special diet for weight loss and had lost 30 kgs in the last 6 months. His vitamin B1 level was undetectable, and symptoms improved with vitamin B1 infusion followed by oral supplementation. Although neuropathy from vitamin B1 deficiency is rare, it can occasionally mimic Guillain-Barre syndrome, and a careful history can be helpful. This is commonly encountered in nutritionally deficient individuals and following gastric bypass surgery. Vitamin B1 deficiency–related neuropathy is usually of axonal type and if treated early, may respond to supplementation (41; 26).
Vignette 3. A 45-year-old female with no significant past medical history presents with progressive paresthesias over the left side of her face and hands more prominently than her feet. The patient denied any changes in vision, gait unsteadiness, focal weakness, urinary or bowel incontinence, or difficulty swallowing or speaking. On neurologic exam she was found to have decreased sensation to pinprick in her left face, hands, interscapular area, thighs, and feet. MRI of the brain was unremarkable. Nerve conduction studies and electromyography were normal. Skin biopsy of the left thigh showed decreased intra-epidermal nerve fiber density. Serum testing revealed elevated antibody levels of tissue transglutaminase IgA, gliadin IgG, and gliadin IgA. There was normal complete blood count, comprehensive metabolic panel, fasting glucose, oral glucose tolerance test, serum Vitamin B12, TSH, gliadin IgA, ANA, anti-dsDNA, SSA, SSB, ESR, and Lyme testing. Duodenal biopsy revealed significant villous atrophy and lymphocytosis. The patient was diagnosed with celiac disease with an associated multifocal small fiber neuropathy and was started on a gluten-free diet.
Biological basis
Etiology and pathogenesis
Peripheral neuropathy may be either inherited or acquired. More than 200 specific types of peripheral neuropathy have been identified, each with characteristic--but usually not distinctive--features (36). Acquired peripheral neuropathies are more common and can be grouped into several broad categories: those caused by systemic disease, those caused by trauma from external agents, and those caused by infections or autoimmune disorders affecting nerve tissue (Table 1).
Neurologic manifestations of COVID-19, including symptoms involving the peripheral nervous system, have been reported. It is not clear to what extent the nervous system involvement is related to a direct involvement of the virus on nervous tissue or to the effect of a robust immune response (52; 54; 61).
Medications, particularly chemotherapies, can lead to neuropathy (70; 62; 50). Immune checkpoint inhibitors can also be associated with neuropathy (21). Additional causes of neuropathy are also continuously being recognized, such as postsurgical inflammatory neuropathy and ischemic monomelic neuropathy (69; 16). Inherited forms of peripheral neuropathy are caused by inborn errors in the genetic code or by new genetic mutations. The most common inherited neuropathies result from abnormalities in genes responsible for neuron cell development, Schwann cell development, myelin sheath maintenance, or myelin sheath folding. These are collectively referred to as Charcot-Marie-Tooth disease, or hereditary motor and sensory neuropathy (11). A rare but important cause of polyneuropathy includes hereditary transthyretin amyloidosis, a progressive disease with a range of clinical manifestations. Patients typically present with polyneuropathy, and nearly 70% exhibit diffuse motor weakness, sensory loss, and autonomic insufficiency; concurrently, over 60% of patients also develop cardiomyopathy (39; 77). Hereditary transthyretin amyloidosis should be recognized as early as possible as disease-modifying therapies are available (02; 03; 04; 10).
The peripheral nervous system is made up of anatomically and functionally distinct neurons, which subserve motor, sensory, and autonomic functions. Cell bodies, or perikarya, of motor nerves that innervate skeletal muscle lie in the anterior horn of the spinal cord. Their axons travel through the anterior spinal roots and peripheral nerve trunks, terminating at the neuromuscular junction. Sensory nerves convey impulses from special receptors or bare nerve endings in the skin and internal organs. Their perikarya lie in sensory ganglia adjacent to the spine (dorsal root ganglia), and their processes extend from the receptor organs in the periphery through the dorsal roots into the spinal cord. Autonomic nerves innervate the heart, glands, and smooth muscles; they consist of preganglionic fibers that emanate from the brainstem and spinal cord and postganglionic fibers that emanate either from the sympathetic ganglia on either side of the thoracic spine or from parasympathetic ganglia embedded in or near the target organ. The various elements of the peripheral nerves are interconnected and communicate with the spinal cord and each other through their processes, spanning the body in a manner analogous to a fine electrical network.
The neuronal processes, or axons, travel as bundles within fascicles in peripheral nerves. Individual axons are enveloped by Schwann cell processes, or myelin sheaths, and are embedded in a loose matrix of connective tissue called the endoneurium. Each fascicle is surrounded by a dense band of connective tissue called the perineurium, which functions as a blood-nerve barrier and helps maintain the specialized endoneurial environment necessary for nerve function. Peripheral nerves are ensheathed by a dense collagenous layer called the epineurium through which blood vessels and lymphatic drainage provide nutrients and drainage to the nerve.
Nerve signals are propagated by the axonal membrane, with myelinated axons conducting impulses faster and at higher frequencies than unmyelinated axons. Each myelinating Schwann cell ensheathes an axon segment of 500 to 1500 µm in length called an internode. Adjacent internodes are separated by 1 µm of unmyelinated axonal segments called nodes of Ranvier. The myelinated fibers conduct impulses from node to node, whereas the internodal membranes remain relatively inert. When demyelination occurs, axonal conduction is slowed or blocked as unmyelinated fibers conduct in a continuous rather than salutatory fashion along their entire length (23).
Epidemiology
Large-scale population-based studies have suggested that 1% to 7% of the general population may have some form of neuropathy depending on location and age group (32). The overall prevalence of peripheral neuropathy (defined by monofilament insensitivity) is about 13.5% in the U.S. population over 40 years of age. The prevalence increases with age, and about 25% to 42% population over the age of 70 years may have peripheral neuropathy with or without diabetes (37). The most common attributable cause of neuropathy is diabetes, which may account for approximately one third of all neuropathies. The remaining two thirds of neuropathies are split between idiopathic and all other known causes (13; 09).
Prevention
Preventative measures vary according to the type of peripheral neuropathy, such as lifestyle modification and avoidance of offending agents. In diabetic neuropathy, intensive glycemic control does not reduce the risk of diabetic neuropathy but does delay the onset (40). Based on a large-scale prospective study from the UK, glycemic control may also have some potential benefit in preventing diabetic neuropathy (06; 67). Based on meta-analyses, exercise interventions may improve glycemic control, balance, and nerve conduction velocities. Combined endurance and sensorimotor training programs appeared to be more beneficial (71; 35). Despite some positive findings of various measures (vitamin E, cryotherapy, compression therapy) suggesting the potential role of some agents in preventing chemotherapy-induced peripheral neuropathy (CIPN), there are methodological limitations, and the most recent guideline from ASCO does not recommend any agents for the prevention of CIPN (50; 55; 48; 79).
Differential diagnosis
When approaching a patient with neuropathy, the differential diagnosis can be broad (Table 1). As discussed earlier, a careful history provides information about the symptoms, distribution, and course of the neuropathy. Medical history, social history, and a review of systems may alert the examiner to a possible systemic, toxic, or nutritional etiology. A thorough family history can uncover a hereditary neuropathy. A detailed neurologic examination is required to confirm the presence of neuropathy and to provide information regarding the distribution, severity, and functional impairment of the disease. As information is gathered and condensed, a narrower differential diagnosis comes into focus, and further testing can help with exact diagnosis (Table 2 and 4). Some etiologies may cause more than one type of presentation. Diabetes, for example, may cause of variety of different clinical presentations (64).
Table 1. A Classification of the Peripheral Neuropathies
|
Etiology |
Distal symmetric presentation |
Multifocal presentation |
Focal presentation |
Autonomic involvement |
|
Endocrine, metabolic and renal diseases | ||||
|
Diabetes |
++ |
+ |
+ |
+ |
|
Uremia |
+ | |||
|
Acromegaly |
+ |
+ | ||
|
Porphyria |
+ |
+ | ||
|
Hypophosphatemia |
+ | |||
|
Critical illness polyneuropathy |
+ | |||
|
Immune-mediated inflammatory neuropathies | ||||
|
Guillain-Barre syndrome |
+ |
+ | ||
|
Chronic inflammatory demyelinating polyneuropathy (CIDP) |
+ (associated with proximal weakness) |
+ | ||
|
Multifocal motor neuropathy |
+ | |||
|
Neuropathy associated with antiganglioside antibodies |
+ |
+ |
+ |
+ |
|
Celiac disease |
+ |
+ |
+ | |
|
Systemic lupus erythematosus, rheumatoid arthritis, Sjogren syndrome |
+ |
+ | ||
|
Vasculitis or microvasculitis |
+ |
+ |
+ | |
|
Postsurgical inflammatory neuropathy |
+ |
+ |
+ | |
|
Cryoglobulinemia |
+ |
+ | ||
|
Sarcoidosis |
+ |
+ |
+ | |
|
Infections | ||||
|
HIV |
+ |
+ |
+ | |
|
COVID-19 |
+ |
+ |
+ | |
|
Hepatitis C |
+ |
+ | ||
|
Hepatitis B |
+ | |||
|
Herpes zoster |
+ |
+ | ||
|
Leprosy |
+ |
+ | ||
|
Lyme disease |
+ |
+ |
+ | |
|
Diphtheria |
+ |
+ | ||
|
Neoplasms and paraneoplastic syndromes | ||||
|
Anti-Hu, CV2, CRMP-5, ganglionic acetylcholine receptor, MAP1B-IgG, voltage-gated calcium channel antibodies |
+ |
+ |
+ | |
|
Anti-Yo, amphiphysin, glial nuclear antibodies |
+ |
+ | ||
|
Anti-MAG IgM kappa |
+ |
+ | ||
|
Caspr2 |
+ |
+ |
+ |
+ |
|
Multiple myeloma |
+ | |||
|
Monoclonal gammopathies |
+ | |||
|
POEMS syndrome and associated anti-VEGF Ab |
+ |
+ |
+ | |
|
Primary amyloidosis |
+ |
+ |
+ |
+ |
|
Lymphoma |
+ |
+ |
+ |
+ |
|
Common entrapment and trauma-related neuropathy | ||||
|
Carpal tunnel syndrome |
+ | |||
|
Ulnar neuropathy at the elbow or wrist |
+ | |||
|
Anterior/posterior interosseous neuropathy |
+ | |||
|
Radial neuropathy in the upper arm |
+ | |||
|
Sciatic neuropathy |
+ | |||
|
Common fibular (peroneal) neuropathy at the knee |
+ | |||
|
Lateral cutaneous nerve of the thigh |
+ | |||
|
Nutritional | ||||
|
Thiamine deficiency |
+ |
+ | ||
|
B12 deficiency |
+ | |||
|
Pyridoxine (B6) (excess or deficiency) |
+ | |||
|
Vitamin E deficiency |
+ | |||
|
Toxin mediated | ||||
|
Alcohol |
+ | |||
|
Nitrous oxide |
+ | |||
|
Thallium |
+ |
+ | ||
|
Lead |
+ | |||
|
Arsenic |
+ |
+ | ||
|
Glue sniffing (n-Hexane) |
+ | |||
|
Acrylamide |
+ | |||
|
Organophosphates |
+ | |||
|
Mercury |
+ |
+ | ||
|
Chemotherapeutic drugs | ||||
|
Taxane (paclitaxel, docetaxel, cabazitaxel) |
+ | |||
|
Platinum analogues (cisplatin, carboplatin, oxaliplatin) |
+ |
+ | ||
|
Vinca alkaloid (vincristine, vinblastine) |
+ |
+ |
+ |
+ |
|
Proteasome inhibitors (primarily bortezomib) |
+ |
+ | ||
|
Thalidomide |
+ | |||
|
Suramin |
+ | |||
|
Other medications | ||||
|
Amiodarone |
+ | |||
|
Chloroquine |
+ | |||
|
Chloramphenicol |
+ | |||
|
Colchicine |
+ | |||
|
Dactinomycin |
+ | |||
|
Dapsone |
+ | |||
|
Ethambutol |
+ |
+ | ||
|
Hydralazine |
+ | |||
|
Isoniazid |
+ | |||
|
Lamivudine |
+ | |||
|
Leflunomide |
+ | |||
|
Linezolid |
+ | |||
|
Metronidazole |
+ | |||
|
Tacrolimus (FK506) |
+ | |||
|
TNF-alpha antagonists |
+ |
+ | ||
|
Hereditary neuropathies | ||||
|
Hereditary neuropathy with predisposition to pressure palsy (HNPP) |
+ |
+ | ||
|
Charcot-Marie-Tooth disease |
+ | |||
|
Hereditary transthyretin amyloidosis (hATTR) |
+ |
+ |
+ |
+ |
|
Hereditary neuralgic amyotrophy |
+ |
+ | ||
|
Refsum disease |
+ |
+ | ||
Table 2. Differential Diagnosis of Peripheral Neuropathy Based on Clinical Time Course
|
Acute onset (days) |
Subacute onset (weeks to months) |
Chronic or insidious onset (years) |
Relapsing remitting course |
|
• Guillain-Barre syndrome (idiopathic and HIV-associated) |
• Toxic agents, medications |
• Hereditary motor sensory neuropathies |
• Guillain-Barre syndrome (idiopathic) |
|
• Critical illness polyneuropathy |
• CIDP |
• CIDP |
• Acute intermittent porphyria |
|
• Infectious (eg, Lyme, diphtheritic neuropathy) |
• Metabolic and collagen vascular (diabetes, renal lupus) |
• Metabolic and collagen vascular (diabetes, renal lupus) |
• Metabolic and collagen vascular (diabetes, renal lupus) |
|
• Toxic agents, medications |
• Paraneoplastic |
• HIV |
• Vasculitis |
|
• Acute intermittent porphyria |
• Nutritional and vitamin deficiency |
• Nutritional and vitamin deficiency |
• CIDP |
|
• Vasculitis |
• Infectious (eg, Lyme, CMV) |
• MGUS |
• Toxic |
|
• Graft vs. host disease |
• Metabolic derangement (diabetes, renal failure) | ||
|
• Vasculitis | |||
|
| |||
Table 3. Positive and Negative Symptoms of Peripheral Neuropathy
|
Type of nerve fiber |
Positive symptoms |
Negative symptoms |
|
Sensory |
• Paresthesia (jabbing, shooting) |
• Lack of sensation |
|
Motor |
• Cramps |
• Weakness |
|
Autonomic |
• Diarrhea |
• Arrhythmia |
Table 4. Partial List of Tests to Consider in Evaluation of Peripheral Neuropathy
|
Basic work-up for distal symmetric neuropathy | |
|
• Complete blood count with differential | |
|
• Comprehensive metabolic panel, including hepatic function test | |
|
• Fasting glucose/2-hour glucose tolerance test | |
|
• Serum protein electrophoresis and immunofixation | |
|
• Kappa/lambda ratio with kappa light chains and lambda light chains | |
|
• Vitamin B12 with methylmalonic acid and homocysteine | |
|
• Erythrocyte sedimentation rate | |
|
• Lipid profile | |
|
Other potential work-up based on clinical presentation | |
|
Blood work | |
|
• ANA | |
|
• CRP | |
|
• Rheumatological markers: rheumatoid factor, SSA, SSB, dsDNA | |
|
• Angiotensin-converting enzyme | |
|
• Vitamin B1, B6, E | |
|
• Heavy metals: copper, zinc, arsenic, mercury | |
|
• Cryoglobulin | |
|
• ANCA | |
|
• Hepatitis A, B, C | |
|
• HIV | |
|
• HTLV | |
|
• Lyme | |
|
• VDRL | |
|
• Paraneoplastic antibodies | |
|
• Nodal/paranodal antibodies (neurofascin 155, IgG4, contactin1) | |
|
• Anti-ganglioside antibodies | |
|
• Anti-gliadin IgG, IgA, and transglutaminase antibody | |
|
Urine analysis | |
|
• Urine protein electrophoresis with immunofixation | |
|
• Bence Jones protein | |
|
• 24-hour heavy metals (mercury, lead, arsenic) | |
|
• Porphobilinogen | |
|
Nerve conduction studies with electromyography | |
|
Autonomic testing | |
|
CSF analysis | |
|
• Cell count | |
|
• Protein | |
|
• Glucose | |
|
• Infectious work-up | |
|
• CSF paraneoplastic antibodies | |
|
Genetic testing in suspected hereditary neuropathy | |
|
Biopsies | |
|
• Skin biopsy (for small fiber neuropathy) | |
|
• Abdominal fat pad biopsy (for amyloid neuropathy) | |
|
• Minor salivary gland biopsy (for Sjogren syndrome) | |
|
• Nerve biopsies for vasculitis or amyloidosis | |
|
Imaging studies | |
|
• MRI of spine, including nerve roots | |
|
• MR neurography of plexi | |
|
• Nerve ultrasound | |
|
• Malignancy work-up with CT chest, abdomen, pelvis, or PET scan (when paraneoplastic process is suspected) | |
Table 5. Etiologies Based on The Pattern of Clinical Presentation
|
Symmetric | ||
|
• Proximal and distal weakness with sensory loss | ||
|
-- Inflammatory demyelinating polyneuropathy (AIDP/CIDP) | ||
|
• Symmetric distal sensory loss with or without distal weakness | ||
|
-- Cryptogenic sensory polyneuropathy (CSPN) | ||
|
-- Metabolic disorders | ||
|
-- Drugs | ||
|
-- Toxins | ||
|
-- Hereditary (Charcot-Marie-Tooth, amyloidosis, and others) | ||
|
• Symmetric weakness without sensory loss and reduced reflexes | ||
|
-- Proximal and distal weakness | ||
|
-- Spinal muscular atrophy | ||
|
-- Distal weakness – hereditary motor neuropathy | ||
|
Symmetric sensory loss and distal areflexia with upper motor neuron findings | ||
|
• B12 deficiency and other causes of combined system degeneration | ||
|
• Copper deficiency (including zinc toxicity) | ||
|
• Inherited disorders (adrenomyeloneuropathy, metachromatic leukodystrophy, Friedreich ataxia) | ||
|
• CSPN + cervical myelopathy | ||
|
Asymmetric | ||
|
• Distal weakness with sensory loss | ||
|
-- Single nerves/regions: consider compressive mononeuropathy and radiculopathy | ||
|
-- Multiple nerves: consider vasculitis, HNPP, MADSAM neuropathy, infectious (leprosy, Lyme, sarcoid, HIV) | ||
|
• Distal weakness without sensory loss | ||
|
-- With upper motor neuron findings: motor neuron disease/amyotrophic lateral sclerosis/primary lateral sclerosis | ||
|
-- Without upper motor neuron findings: progressive muscular atrophy, multifocal motor neuropathy, MAMA, juvenile monomelic amyotrophy | ||
|
• Proximal and distal weakness with sensory loss | ||
|
-- Polyradiculopathy or plexopathy | ||
|
-- Meningeal carcinomatosis | ||
|
-- Lymphomatosis | ||
|
-- Sarcoidosis | ||
|
-- Amyloidosis | ||
|
-- Lyme | ||
|
-- Idiopathic | ||
|
-- Hereditary (HNPP, familial) | ||
|
Neuropathies associated with autonomic signs and symptoms | ||
|
• Hereditary sensory and autonomic neuropathies | ||
|
• Diabetes | ||
|
• Guillain-Barre syndrome | ||
|
• Amyloid | ||
|
• Porphyria | ||
|
• Fabry | ||
Diagnostic workup
Blood studies can aid in the diagnosis of inflammatory, paraneoplastic, infectious, endocrine, metabolic, toxic, nutritional, or hereditary causes of neuropathies. The most common pattern of polyneuropathy is a length-dependent, distal symmetric sensory greater than motor polyneuropathy (09). Initial laboratory screening for causes of distal symmetric polyneuropathy usually includes fasting blood glucose, comprehensive metabolic panel, liver function test, complete blood count and differential, serum vitamin B12, and serum immunofixation electrophoresis (IFE) (25). If there is no definite evidence of diabetes mellitus by routine testing of blood glucose, testing for impaired glucose tolerance may be considered in distal symmetric sensory polyneuropathy (25). CSF studies are reserved for suspected autoimmune, infectious, or neoplastic etiologies.
Electrodiagnostic studies, including electromyography and nerve conduction studies, may be used to confirm the presence of peripheral neuropathy; reveal whether the underlying process is demyelination or axon loss; determine whether motor, large fiber sensory, or a combination of fibers are involved; assess the severity and distribution pattern of neuropathy; and follow the course of the disease. Nerve conduction studies are of limited value in assessing proximal lesions, but electromyography of proximal muscles can assess involvement of motor axons or neurons. Additionally, nerve conduction studies largely assess the function of large diameter nerve fibers, whereas the majority of axons are small, and commonly employed electromyography/nerve conduction studies techniques fail to detect small fiber neuropathy (14). In case of normal nerve conduction studies when investigating sensory polyneuropathy, epidermal nerve fiber density and autonomic function testing provide complementary diagnostic data as these modalities assess small unmyelinated fibers.
Autonomic and small fiber neuropathies may be assessed using epidermal nerve fiber density, sweat gland nerve fiber density, autonomic function testing, or quantitative sensory testing. Proposed diagnostic “gold standards” for small fiber neuropathies include the presence of at least two abnormal results in the clinical, quantitative sensory testing, and skin biopsy examinations (19). Epidermal skin punch biopsy is now commonly employed to measure epidermal nerve density using the nerve specific marker PGP 9.5 and is characteristically abnormal when conventional electrodiagnostic studies are normal in small fiber neuropathies (47; 24; 34). It can also be used to quantitate sweat gland nerve fiber density and is complementary to epidermal nerve fiber density measurement. Quantitative sensory testing is a psychophysical test dependent on factors such as subject cooperation, alertness, site of stimulation, and site of study. It is used extensively in clinical trials but is not widely accepted for routine clinical application. Somatosensory evoked potentials are sometimes helpful when severe peripheral nerve disease is present and nerve conduction studies are inadequate, or when the afferent nerves to be studied present insurmountable technical difficulties. They are also extremely helpful in the evaluation of chronic inflammatory sensory polyradiculopathy (CISP) and CISP-plus (65).
Nerve biopsy is most helpful once adequate clinical, laboratory, and electrodiagnostic evaluations have been performed. Its indications are very limited, and the overwhelming majority of neuropathy patients do not require nerve biopsy to establish their diagnosis. Nerve biopsy leads to permanent sensory loss in that particular nerve distribution and is avoided unless indicated. Nerve biopsy can be particularly useful in the diagnosis of autoimmune or vasculitic neuropathies, sarcoidosis, or amyloidosis (80).
Genetic testing may play an important role in the workup and diagnosis of peripheral neuropathy, and there are multiple commercially available genetic panels. It is becoming increasingly important to identify patients with certain hereditary neuropathies as future gene therapy and molecular-based therapies become available (11).
Magnetic resonance imaging (MRI) can aid in the identification of structural spinal pathology that can cause neuropathy. MR neurography can be similarly helpful in diagnosing abnormalities of the thoracic outlet, brachial plexus, lumbosacral plexus, and peripheral nerves. MRI with contrast of the spine or the lumbosacral or brachial plexus can aid in the identification of inflammatory lesions, such as chronic inflammatory demyelinating polyneuropathy or meningitis (22; 53; 72; 51).
High-resolution ultrasound is a noninvasive diagnostic tool that can accurately identify focal nerve enlargement seen with focal nerve entrapments. It can also identify multifocal or diffuse nerve enlargement to aid in the diagnosis of hereditary and inflammatory neuropathies (78). A prospective multicenter study showed that there is little interobserver variability in nerve ultrasound, even across different hospital sites, using different sonographic devices. Therefore, nerve ultrasound is a reproducible tool for diagnostics in routine clinical practice and research (73).
Advanced techniques to be considered for further evaluation of peripheral neuropathy include corneal confocal microscopy and laser Doppler image flare. Corneal confocal microscopy images the subbasal nerve plexus of the cornea. Reductions in corneal nerve fiber density and fiber length correspond to polyneuropathy severity. It is noninvasive, repeatable, and particularly useful in the evaluation of length-independent neuropathies due to the proximal location. Limitations include a lack of hardware and personnel for the procedure to be performed (12; 43).
Laser Doppler image flare evaluates the axon reflex response to heat stimulus with Doppler. The area of vasodilation due to neurogenic flare is measured, and the flare area is reduced in neuropathy or in the setting of local anesthetic. It has also been used to demonstrate early sequelae of diabetes prior to detection of neuropathy with other methods (01).
Management
Apart from acquired inflammatory neuropathy, compressive neuropathies, and some neuropathies of infectious etiology, the majority of neuropathies are not curable. Therapy is often directed at symptomatic management, supportive care, and improving quality of life (09).
Acquired inflammatory neuropathies (such as CIDP) often respond to standard immunotherapy with glucocorticoid, intravenous and subcutaneous immunoglobulin, and plasmapheresis (49; 76). However, acute inflammatory demyelinating polyneuropathy does not respond to glucocorticoids (38). Other autoimmune inflammatory neuropathies associated with systemic autoimmune diseases, including neuropathy associated with checkpoint inhibitors, respond to judicious short-term use of glucocorticoids as well as immunoglobulin and plasma exchange (21; 31; 18). In more refractory cases, B-cell depletion therapy (such as rituximab) or cyclophosphamide can be used (57).
Neuropathic pain and muscle cramps are often prominent symptoms of peripheral neuropathy. Tricyclic antidepressants (amitriptyline and nortriptyline), anticonvulsants (gabapentin and pregabalin), and serotonin-norepinephrine reuptake inhibitors (duloxetine and venlafaxine) are commonly used to treat neuropathic pain (07; 09). Even in the absence of strong comparative data, the European Federation of Neurologic Societies has previously recommended that these drugs have similar efficacy in painful polyneuropathy (07). One large-scale study suggested essentially similar efficacy of pregabalin, amitriptyline, and duloxetine in painful diabetic polyneuropathy (OPTION-DM). Combination therapy of drugs with different mechanisms of action can be considered when response to monotherapy is suboptimal (74). However, only duloxetine and pregabalin are approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetic neuropathic pain (09). Treatment approaches are similar for any painful neuropathy. A large-scale study from the U.S. suggested possibly better performance of nortriptyline and duloxetine in treating patients with cryptogenic sensory polyneuropathy (08). Duloxetine is the only agent with moderate evidence to be used in painful chemotherapy-induced peripheral neuropathy (CIPN) (50). In the absence of any clear-cut superiority of any of these medications in most of the situations, treatment decisions are usually driven by patients’ comorbidities and potential adverse effects of an individual agent in discussion between the clinician and the patient. Rarely, there is a role for oral opiate or tramadol. The use of tramadol and tapentadol for chronic neuropathic pain is strongly discouraged due to limited data on long-term efficacy, risk of abuse potential being higher than that of morphine, and increased all-cause mortality (07; 60). Spinal cord stimulator can be helpful in refractory painful diabetic neuropathy (58).
Multiple other approaches, including topical agents, anticonvulsants, and antidepressants, are used with variable benefits and limited evidence. Often, a sequential trial of titration to effective dose, side effects, or nonefficacy is needed. Patient education is also important and may include suggestions for regular foot inspection, orthopedic shoes, podiatric evaluation, as well as fall and injury prevention, such as avoidance of loose rugs and testing water temperature with the hands or elbows. Furthermore, nutritional deficiencies should be addressed. Based on level II evidence, a systematic review suggested that vitamin B12 may have a beneficial effect on post-herpetic neuralgia; the evidence was weaker for painful peripheral neuropathy (42). Despite growing interest in ketamine for neuropathic pain and some potential benefit in terms of pain control, the quality of data is limited by heterogeneity in study and dosage and mode of administration (29). Significant adverse effects were reported, including psychedelic effects. Similarly, botulinum toxin A may also have some benefit in treating neuropathic pain, but it is not recommended as a first-line agent (30).
We are in an era of medicine wherein specific genetic and molecular therapies are available for a number of neurologic diseases. For example, in hereditary transthyretin amyloidosis neuropathy, there are three disease-modifying therapies available. Both patisiran and vutrisiran, silencing or small interfering RNAs, and inotersen, an antisense oligonucleotide, have been shown to improve multiple clinical manifestations of hereditary transthyretin amyloidosis. These drugs cause the degradation of mutant and wild-type TTR mRNA and are FDA-approved in the U.S. for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults (02; 10; 63). Lacosamide showed benefit in patients with sodium channel 9 mutation–related small fiber neuropathy (mutations in SCN9A, encoding for Nav1.7) (17). Therefore, as novel therapies continue to be discovered we expect that more options will become available to treat various neuropathies.
References
- 01
- Abraham A, Alabdali M, Alsulaiman A, et al. Laser Doppler flare imaging and quantitative thermal thresholds testing performance in small and mixed fiber neuropathies. PLoS One 2016;11(11):e0165731. PMID 27824912
- 02
- Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018;379(1):11-21. PMID 29972753
- 03
- Adams D, Polydefkis M, Gonzalez-Duarte A, et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurol 2021;20(1):49-59. PMID 33212063
- 04
- Adams D, Tournev IL, Taylor MS, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid 2023;30(1):1-9. PMID 35875890
- 05
- Alport AR, Sander HW. Clinical approach to peripheral neuropathy: anatomic localization and diagnostic testing. Continuum (Minneap Minn) 2012;18(1):13-38. PMID 22810068
- 06
- Anonymous. Implications of the United Kingdom Prospective Diabetes Study. American Diabetes Association. Diabetes Care 1998;21(12):2180-4. PMID 9839113
- 07
- Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17(9):1113-e88. PMID 20402746
- 08
- Barohn RJ, Gajewski B, Pasnoor M, et al. Patient assisted intervention for neuropathy: comparison of treatment in real life situations (PAIN-CONTRoLS): Bayesian adaptive comparative effectiveness randomized trial. JAMA Neurol 2021;78(1):68-76. PMID 32809014
- 09
- Barrell K, Smith AG. Peripheral neuropathy. Med Clin North Am 2019;103(2):383-97. PMID 30704689
- 10
- Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 2018;379(1):22-31. PMID 29972757
- 11
- Bird TD. Charcot-Marie-Tooth hereditary neuropathy overview. In: Adam MP, Mirzaa GM, Pagon RA, editors. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle, 2023.
- 12
- Brines M, Culver DA, Ferdousi M, et al. Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathy. Sci Rep 2018;8(1):4734. PMID 29549285
- 13
- Burns TM, Mauermann ML. The evaluation of polyneuropathies. Neurology 2011;76(7 Suppl 2):S6-13. PMID 21321354
- 14
- Callaghan BC, Kerber KA, Lisabeth LL, et al. Role of neurologists and diagnostic tests on the management of distal symmetric polyneuropathy. JAMA Neurol 2014;71(9):1143-9. PMID 25048157
- 15
- Chin RL, Sander HW, Brannagan TH, et al. Celiac neuropathy. Neurology 2003;60(10):1581-5. PMID 12771245
- 16
- Datta S, Mahal S, Govindarajan R. Ischemic monomelic neuropathy after arteriovenous fistula surgery: clinical features, electrodiagnosic findings, and treatment. Cureus 2019;11(7):e5191. PMID 31565598
- 17
- de Greef BTA, Hoeijmakers JGJ, Geerts M, et al. Lacosamide in patients with Nav1.7 mutations-related small fibre neuropathy: a randomized controlled trial. Brain 2019;142(2):263-75. PMID 30649227
- 18
- De Souza JM, Trevisan TJ, Sepresse SR, Londe AC, Franca Junior MC, Appenzeller S. Peripheral neuropathy in systemic autoimmune rheumatic diseases-diagnosis and treatment. Pharmaceuticals (Basel) 2023;16(4):587. PMID 37111344
- 19
- Devigili G, Tugnoli V, Penza P, et al. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain 2008;131:1912-25. PMID 18524793
- 20
- Doughty CT, Seyedsadjadi R. Approach to peripheral neuropathy for the primary care clinician. Am J Med 2018;131(9):1010-6. PMID 29408540
- 21
- Dubey D, David WS, Amato AA, et al. Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology 2019;10;93(11):e1093-103. PMID 31405908
- 22
- Duggins AJ, McLeod JG, Pollard JD, et al. Spinal root and plexus hypertrophy in chronic inflammatory demyelinating polyneuropathy. Brain 1999;122(Pt 7):1383-90. PMID 10388803
- 23
- Dyck PJ, Thomas PK, Griffin JW, et al, editors. Peripheral neuropathy, 4th ed. Philadelphia: WB Saunders, 2005.
- 24
- England JD, Gronseth GS, Franklin G, et al. Practice Parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology 2009a;72(2):185-192. PMID 19056666
- 25
- England JD, Gronseth GS, Franklin G, et al. Practice Parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology 2009b;72(2):177-84. PMID 19056667
- 26
- Faigle R, Mohme M, Levy M. Dry beriberi mimicking Guillain-Barre syndrome as the first presenting sign of thiamine deficiency. Eur J Neurol 2012;19(2):e14-5. PMID 22136604
- 27
- Freeman R. Autonomic peripheral neuropathy. Continuum (Minneap Minn) 2020;26(1):58-71. PMID 31996622
- 28
- Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci 2011;161(1-2):46-8. PMID 21393070
- 29
- Guimaraes Pereira JE, Ferreira Gomes Pereira L, Mercante Linhares R, Darcy Alves Bersot C, Aslanidis T, Ashmawi HA. Efficacy and safety of ketamine in the treatment of neuropathic pain: A systematic review and meta-analysis of randomized controlled trials. J Pain Res 2022;15:1011-37. PMID 35431578
- 30
- Gupta AD, Edwards S, Smith J, et al. A systematic review and meta-analysis of efficacy of botulinum toxin A for neuropathic pain. Toxins (Basel) 2022;14(1):36. PMID 35051013
- 31
- Gwathmey KG, Satkowiak K. Peripheral nervous system manifestations of rheumatological diseases. J Neurol Sci 2021;424:117421. PMID 33824004
- 32
- Hanewinckel R, Drenthen J, van Oijen M, Hofman A, van Doorn PA, Ikram MA. Prevalence of polyneuropathy in the general middle-aged and elderly population. Neurology 2016a;87(18):1892-8. PMID 27683845
- 33
- Hanewinckel R, van Oijen M, Ikram MA, van Doorn PA. The epidemiology and risk factors of chronic polyneuropathy. Eur J Epidemiol 2016b;31(1):5-20. PMID 26700499
- 34
- Hays AP. Utility of skin biopsy to evaluate peripheral neuropathy. Curr Neurol Neurosci Rep 2010;10(2):101-10. PMID 20425234
- 35
- Hernando-Garijo I, Medrano-de-la-Fuente R, Mingo-Gomez MT, Lahuerta Martin S, Ceballos-Laita L, Jimenez-Del-Barrio S. Effects of exercise therapy on diabetic neuropathy: a systematic review and meta-analysis. Physiother Theory Pract 2023;1-14. PMID 37341684
- 36
- Herskovitz S, Scelsa SN, Schaumburg HH. Peripheral neuropathies in clinical practice. New York: Oxford University Press, 2010:24-55.
- 37
- Hicks CW, Wang D, Windham BG, Matsushita K, Selvin E. Prevalence of peripheral neuropathy defined by monofilament insensitivity in middle-aged and older adults in two US cohorts. Sci Rep 2021;11(1):19159. PMID 34580377
- 38
- Hughes RA, Brassington R, Gunn AA, van Doorn PA. Corticosteroids for Guillain-Barre syndrome. Cochrane Database Syst Rev 2016;10(10):CD001446. PMID 27775812
- 39
- Hund E, Linke RP, Willig F, Grau A. Transthyretin-associated neuropathic amyloidosis: pathogenesis and treatment. Neurology 2001;56(4):431-5. PMID 11261421
- 40
- Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010;376(9739):419-30. PMID 20594588
- 41
- Juhasz-Pocsine K, Rudnicki SA, Archer RL, Harik SI. Neurologic complications of gastric bypass surgery for morbid obesity. Neurology 2007;68(21):1843-50. PMID 17515548
- 42
- Julian T, Syeed R, Glascow N, Angelopoulou E, Zis P. B12 as a treatment for peripheral neuropathic pain: a systematic review. Nutrients 2020;12(8):2221. PMID 32722436
- 43
- Kalteniece A, Ferdousi M, Azmi S, et al. Corneal confocal microscopy detects small nerve fibre damage in patients with painful diabetic neuropathy. Sci Rep 2020;10(1):3371. PMID 32099076
- 44
- Kazamel M, Stino AM, Smith AG. Metabolic syndrome and peripheral neuropathy. Muscle Nerve 2021;63(3):285-93. PMID 33098165
- 45
- Kempler P, Amarenco G, Freeman R, et al. Management strategies for gastrointestinal, erectile, bladder, and sudomotor dysfunction in patients with diabetes. Diabetes Metab Res Rev 2011;27(7):665-77. PMID 21748841
- 46
- Kulkantrakorn K. Pyridoxine-induced sensory ataxic neuronopathy and neuropathy: revisited. Neurol Sci 2014;35(11):1827-30. PMID 25056196
- 47
- Lauria G, Cornblath DR, Johansson O, et al. EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy. Eur J Neurol 2005;12(10):747-58. PMID 16190912
- 48
- Leen AJ, Yap DWT, Teo CB, et al. A systematic review and meta-analysis of the effectiveness of neuroprotectants for paclitaxel-induced peripheral neuropathy. Front Oncol 2022;11:763229. PMID 35070969
- 49
- Levine TD, Katz JS, Barohn R, et al. Review process for IVIg treatment: lessons learned from INSIGHTS neuropathy study. Neurol Clin Pract 2018;8(5):429-36. PMID 30564497
- 50
- Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325-48. PMID 32663120
- 51
- Martin-Noguerol T, Montesinos P, Barousse R, Luna A. RadioGraphics update: functional MR neurography in evaluation of peripheral nerve trauma and postsurgical assessment. Radiographics 2021;41(2):E40-4. PMID 33646898
- 52
- Maury A, Lyoubi A, Peiffer-Smadja N, et al. Neurological manifestations associated with SARS-CoV-2 and other coronaviruses: a narrative review for clinicians. Rev Neurol (Paris) 2021;177(1-2):51-64. PMID 33446327
- 53
- Mazal AT, Faramarzalian A, Samet JD, Gill K, Cheng J, Chhabra A. MR neurography of the brachial plexus in adult and pediatric age groups: evolution, recent advances, and future directions. Expert Rev Med Devices 2020;17(2):111-22. PMID 31964194
- 54
- Meppiel E, Peiffer-Smadja N, Maury A, et al. Neurologic manifestations associated with COVID-19: a multicentre registry. Clin Microbiol Infect 2021;27(3):458-66. PMID 33189873
- 55
- Miao H, Li R, Chen D, et al. Protective effects of vitamin E on chemotherapy-induced peripheral neuropathy: a meta-analysis of randomized controlled trials. Ann Nutr Metab 2021;77(3)127-37. PMID 34148036
- 56
- Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat Rev 2014;40(7):872-82. PMID 24830939
- 57
- Muley SA, Jacobsen B, Parry G, et al. Rituximab in refractory chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2020;61(5):575-9. PMID 31922613
- 58
- Petersen EA, Stauss TG, Scowcroft JA, et al. Effect of high-frequency (10-kHz) spinal cord stimulation in patients with painful diabetic neuropathy: a randomized clinical trial. JAMA Neurol 2021;78(6):687-98. PMID 33818600
- 59
- Polydefkis M, Griffin JW, McArthur J. New Insights into diabetic polyneuropathy. JAMA 2003;290(10):1371-6. PMID 12966130
- 60
- Price R, Smith D, Franklin G, et al. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary: Report of the AAN Guideline Subcommittee. Neurology 2022;98(1):31-43. PMID 34965987
- 61
- Rass V, Beer R, Schiefecker AJ, et al. Neurological outcome and quality of life 3 months after COVID-19: A prospective observational cohort study. Eur J Neurol 2021;28(10):3348-59. PMID 33682276
- 62
- Roy B, Das A, Ashish K, et al. Neuropathy with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis. Neurology 2019;93(2):e143-8. PMID 31167931
- 63
- Russo M, Gentile L, Toscano A, Aguennouz M, Vita G, Mazzeo A. Advances in treatment of ATTRv amyloidosis: state of the art and future prospects. Brain Sci 2021;10(12):952. PMID 33316911
- 64
- Sasaki H, Kawamura N, Dyck PJ, Dyck PJB, Kihara M, Low PA. Spectrum of diabetic neuropathies. Diabetol Int 2020;11(2):87-96. PMID 32206478
- 65
- Shelly S, Shouman K, Paul P, et al. Expanding the spectrum of chronic immune sensory polyradiculopathy: CISP-plus. Neurology 2021;96(16):e2078-89. PMID 33653905
- 66
- Silsby M, Feldman EL, Dortch RD, et al. Advances in diagnosis and management of distal sensory polyneuropathies. J Neurol Neurosurg Psychiatry 2023. [Epub ahead of print] PMID 36997315
- 67
- Smith S, Normahani P, Lane T, Hohenschurz-Schmidt D, Oliver N, Davies HW. Prevention and management strategies for diabetic neuropathy. Life (Basel) 2022;12(8):1185. PMID 36013364
- 68
- Spallone V, Ziegler D, Freeman R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev 2011;27(7):639-53. PMID 21695768
- 69
- Staff NP, Engelstad J, Klein CJ, et al. Post-surgical inflammatory neuropathy. Brain 2010;133(10):2866-80. PMID 20846945
- 70
- Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol 2017;81(6):772-81. PMID 28486769
- 71
- Streckmann F, Balke M, Cavaletti G, et al. Exercise and neuropathy: systematic review with meta-analysis. Sports Med 2022;52(5):1043-65. PMID 34964950
- 72
- Su X, Kong X, Lu Z, et al. Use of magnetic resonance neurography for evaluating the distribution and patterns of chronic inflammatory demyelinating polyneuropathy. Korean J Radiol 2020;21(4):483-93. PMID 32193896
- 73
- Telleman JA, Herraets IJT, Goedee HS, et al. Nerve ultrasound: a reproducible diagnostic tool in peripheral neuropathy. Neurology 2018;10.1212/WNL.000000000000685. PMID 30593519
- 74
- Tesfaye S, Sloan G, Petrie J, et al. Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial. Lancet 2022;400(10353):680-90. PMID 36007534
- 75
- Tesfaye S, Vileikyte L, Rayman G, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev 2011;27(7):629-38. PMID 21695762
- 76
- van Lieverloo GGA, Peric S, Doneddu PE, et al. Corticosteroids in chronic inflammatory demyelinating polyneuropathy: a retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone. J Neurol 2018;265(9):2052-9. PMID 29968199
- 77
- Waddington-Cruz M, Ackermann EJ, Polydefkis M, et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial. Amyloid 2018;25(3):180-8. PMID 30169969
- 78
- Walker FO. Ultrasonography in peripheral nervous system diagnosis. Continuum (Minneap Minn) 2017;23(5, Peripheral Nerve and Motor Neuron Disorders):1276-94. PMID 28968362
- 79
- Wang M, Pei Z, Molassiotis A. Recent advances in managing chemotherapy-induced peripheral neuropathy: a systematic review. Eur J Oncol Nurs 2022;58:102134. PMID 35421796
- 80
- Weis J, Brandner S, Lammens M, Sommer C, Vallat JM. Processing of nerve biopsies: a practical guide for neuropathologists. Clin Neuropathol 2012;31(1):7-23. PMID 22192700
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Authors
-
Mazen M Dimachkie MD
Dr. Dimachkie, Director of the Neuromuscular Disease Division and Executive Vice Chairman for Research Programs, Department of Neurology, The University of Kansas Medical Center received consultant honorariums from Abata/Third Rock, Abcuro, Amicus, ArgenX, Astellas, Cabaletta Bio, Catalyst, CNSA, Covance/LabCorp, CSL Behring, Dianthus, EMD Serono/Merck, Horizon, Ig Society Inc, Ipsen, Janssen, Octapharma, Priovant, Ra Pharma/UCB Biopharma, Sanofi Genzyme, Shire/Takeda, Treat NMD/TACT, and Valenza Bio. Dr. Dimachikie also received research grants from Alexion/Astra Zaneca, Amicus, Astellas, Catalyst, CSL Behring, EMD Serono/Merck, Genentech, Grifols, GSK, Horizon, Janssen, Mitsubishi Tanabe Pharma, MT Pharma, Novartis, Octapharma, Priovant, Ra Pharma/UCB Biopharma, Sanofi Genzyme, Sarepta Therapeutics, Shire/Takeda, and TMA.
See Profile -
Bhaskar Roy MBBS MHS
Dr. Roy of Yale Medicine received a consultation fee from Argenx and owns stock in Cabaletta Bio.
See Profile
Editor
-
Louis H Weimer MD
Dr. Weimer of Columbia University has no relevant financial relationships to disclose.
See Profile
Former Authors
- Howard W Sander MD
- Mordechai Z Smith MD
- Norman Latov MD PhD (original author), Olajide Williams MD MSc, Vanessa Gopez MD, Scott N Grossman MD, Patrick M Kwon MD, and Amanda B Murphy MD
Patient Profile
- Age range of presentation
-
- 0 month to 65+ years
- Sex preponderance
-
- male=female
- Heredity
-
- heredity may be a factor
- Population groups selectively affected
-
- Polyneuropathy is more common among the elderly and among those in higher socioeconomic brackets worldwide.
- Occupation groups selectively affected
-
- none selectively affected
ICD & OMIM codes
- ICD-10
-
- Other disorders of trigeminal nerve: G50.8
- Disorder of trigeminal nerve, unspecified: G50.9
- Other disorders of facial nerve: G51.8
- Disorder of facial nerve, unspecified: G51.9
- Disorders of olfactory nerve: G52.0
- Disorders of glossopharyngeal nerve: G52.1
- Disorders of vagus nerve: G52.2
- Disorders of hypoglossal nerve: G52.3
- Disorders of multiple cranial nerves: G52.7
- Disorders of other specified cranial nerves: G52.8
- Cranial nerve disorder, unspecified: G52.9
- Multiple cranial nerve palsy in sarcoidosis: D86.82
- Multiple cranial nerve palsy in syphilis: A52.15
- Postherpetic trigeminal neuralgia: B02.22
- Cranial nerve disorders in diseases classified elsewhere: G53
- Disorders of acoustic nerve: H93.3
- Disorders of optic nerve: H46, H47.0
- Cranial nerve disorders in diseases classified elsewhere: G53
- Neuralgia or neuritis NOS: M79.2
- Radiculitis NOS: M54.10
- Radiculopathy NOS: M54.10
- Neuritis or radiculitis brachial NOS: M54.13
- Neuritis or radiculitis thoracic NOS: M54.14
- Neuritis or radiculitis lumbar NOS: M54.16
- Neuritis or radiculitis lumbosacral NOS: M54.17
- Brachial plexus disorders: G54.0
- Lumbosacral plexus disorders: G54.1
- Cervical root disorders, not elsewhere classified: G54.2
- Thoracic root disorders, not elsewhere classified: G54.3
- Lumbosacral root disorders, not elsewhere classified: G54.4
- Neuralgic amyotrophy: G54.5
- Other nerve root and plexus disorders: G54.8
- Nerve root and plexus disorder, unspecified: G54.9
- Mononeuropathies of upper limb: Class of G56 codes
- Mononeuropathies of lower limb: Class of G57 codes
- Intercostal neuropathy: G58.0
- Mononeuritis multiplex: G58.7
- Other specified mononeuropathies: G58.8
- Mononeuropathy, unspecified: G58.9
- Diabetic mononeuropathy: E08 to E13 with .41
- Syphilitic nerve paralysis: A52.19
- Syphilitic neuritis: A52.15
- Tuberculous mononeuropathy: A17.83
- Mononeuropathy in diseases classified elsewhere: G59
- Hereditary motor and sensory neuropathy: G60.0
- Refsum disease: G60.1
- Neuropathy in association with hereditary ataxia: G60.2
- Idiopathic progressive neuropathy: G60.3
- Other hereditary and idiopathic neuropathies: G60.8
- Hereditary and idiopathic neuropathy, unspecified: G60.9
- Guillain-Barre syndrome: G61.0
- Serum neuropathy: G61.1
- Other inflammatory polyneuropathies: G61.8
- Chronic inflammatory demyelinating polyneuritis: G61.81
- Multifocal motor neuropathy: G61.82
- Other inflammatory polyneuropathies: G61.89
- Inflammatory polyneuropathy, unspecified: G61.9
- Drug-induced polyneuropathy: G62.0
- Alcoholic polyneuropathy: G62.1
- Polyneuropathy due to other toxic agents: G62.2
- Other specified polyneuropathies: G62.8
- Critical illness polyneuropathy: G62.81
- Radiation-induced polyneuropathy: G62.82
- Other specified polyneuropathies: G62.89
- Polyneuropathy, unspecified: G62.9
- Polyneuropathy in infectious mononucleosis: B27.0 – B27.9 with 1
- Other neurologic disorders in Lyme disease: A69.22
- Mumps polyneuropathy: B26.84
- Postherpetic polyneuropathy: B02.23
- Rheumatoid polyneuropathy with rheumatoid arthritis: M05.5
- Systemic sclerosis with polyneuropathy: M34.83
- Other organ or system involvement in systemic lupus erythematosus: M32.19
- Polyneuropathy in diseases classified elsewhere: G63
- Other disorders of peripheral nervous system: G64
- Sequelae of Guillain-Barré syndrome: G65.0
- Sequelae of other inflammatory polyneuropathy: G65.1
- Sequelae of toxic polyneuropathy: G65.2
- Other idiopathic peripheral autonomic neuropathy: G90.09
- Multi-system degeneration of the autonomic nervous system: G90.3
- Other disorders of autonomic nervous system: G90.8
- Disorder of autonomic nervous system, unspecified: G90.9
- Other postprocedural complications and disorders of nervous system: G97.82
- Other disorders of nervous system: G98.8
- Autonomic neuropathy in diseases classified elsewhere: G99.0
- Other specified disorders of nervous system in diseases classified elsewhere: G99.8
- Paraneoplastic neuromyopathy and neuropathy: G13.0
- Uremic neuropathy: N18.8
- Deficiency of other specified B group vitamins: E53.8
- Neuropathic heredofamilial amyloidosis: E85.1
- Light chain (AL) amyloidosis: E85.81
- OMIM
-
- Amyloidosis hereditary, transthyretin related: 105210
- Amyotrophy, hereditary neuralgic: 162100
- Charcot-Marie-Tooth disease, axonal, autosomal dominant, Type 2A2A: 609260
- Charcot-Marie-Tooth disease, axonal, autosomal recessive, Type 2A2B: 617087
- Charcot-Marie-Tooth disease, axonal, type 2A1: 118210
- Charcot-Marie-Tooth disease, axonal, type 2B: 600882
- Charcot-Marie-Tooth disease, axonal, type 2B1: 605588
- Charcot-Marie-Tooth disease, axonal, type 2B2: 605589
- Charcot-Marie-Tooth disease, axonal, type 2CC: 616924
- Charcot-Marie-Tooth disease, axonal, type 2D: 601472
- Charcot-Marie-Tooth disease, axonal, type 2DD: 618036
- Charcot-Marie-Tooth disease, axonal, type 2E: 607684
- Charcot-Marie-Tooth disease, axonal, type 2EE: 618400
- Charcot-Marie-Tooth disease, axonal, type 2F: 606595
- Charcot-Marie-Tooth disease, axonal, type 2H: 607731
- Charcot-Marie-Tooth disease, axonal, type 2I: 607677
- Charcot-Marie-Tooth disease, axonal, type 2J: 607736
- Charcot-Marie-Tooth disease, axonal, type 2K: 607831
- Charcot-Marie-Tooth disease, axonal, type 2L: 608673
- Charcot-Marie-Tooth disease, axonal, type 2N: 613287
- Charcot-Marie-Tooth disease, axonal, type 2O: 614228
- Charcot-Marie-Tooth disease, axonal, type 2P: 614436
- Charcot-Marie-Tooth disease, axonal, type 2Q: 615025
- Charcot-Marie-Tooth disease, axonal, type 2R: 615490
- Charcot-Marie-Tooth disease, axonal, type 2S: 616155
- Charcot-Marie-Tooth disease, axonal, type 2T: 617017
- Charcot-Marie-Tooth disease, axonal, type 2U: 616280
- Charcot-Marie-Tooth disease, axonal, type 2V: 616491
- Charcot-Marie-Tooth disease, axonal, type 2W: 606625
- Charcot-Marie-Tooth disease, axonal, type 2X: 616668
- Charcot-Marie-Tooth disease, axonal, type 2Y: 616687
- Charcot-Marie-Tooth disease, axonal, type 2Z: 616688
- Charcot-Marie-Tooth disease, axonal, with vocal cord paresis, autosomal recessive: 607706
- Charcot-Marie-Tooth disease, demyelinating, Type 1A: 118220
- Charcot-Marie-Tooth disease, demyelinating, Type 1B: 118200
- Charcot-Marie-Tooth disease, demyelinating, Type 1C: 601098
- Charcot-Marie-Tooth disease, demyelinating, Type 1D: 607678
- Charcot-Marie-Tooth disease, demyelinating, Type 1F: 307734
- Charcot-Marie-Tooth disease, demyelinating, Type 1G: 618279
- Charcot-Marie-Tooth disease, demyelinating, Type 4F: 614895
- Charcot-Marie-Tooth disease, dominant intermediate A: 606483
- Charcot-Marie-Tooth disease, dominant intermediate B: 606482
- Charcot-Marie-Tooth disease, dominant intermediate C: 608323
- Charcot-Marie-Tooth disease, dominant intermediate D: 607791
- Charcot-Marie-Tooth disease, dominant intermediate E: 614455
- Charcot-Marie-Tooth disease, dominant intermediate F: 615185
- Charcot-Marie-Tooth disease, dominant intermediate G: 617882
- Charcot-Marie-Tooth disease, Guadalajara neuronal type: 118230
- Charcot-Marie-Tooth disease, recessive intermediate A: 608340
- Charcot-Marie-Tooth disease, recessive intermediate B: 613641
- Charcot-Marie-Tooth disease, recessive intermediate C: 615376
- Charcot-Marie-Tooth disease, recessive intermediate D: 616039
- Charcot-Marie-Tooth disease, type 4A: 214400
- Charcot-Marie-Tooth disease, type 4B1: 601382
- Charcot-Marie-Tooth disease, type 4B2: 604563
- Charcot-Marie-Tooth disease, type 4B3: 615284
- Charcot-Marie-Tooth disease, type 4C: 601596
- Charcot-Marie-Tooth disease, type 4D: 601455
- Charcot-Marie-Tooth disease, type 4H: 609311
- Charcot-Marie-Tooth disease, type 4J: 611228
- Charcot-Marie-Tooth disease, type 4K: 616684
- Charcot-Marie-Tooth disease, X-linked dominant, 1: 302800
- Charcot-Marie-Tooth disease, X-linked dominant, 6: 3000905
- Charcot-Marie-Tooth disease, X-linked recessive, 2: 302801
- Charcot-Marie-Tooth disease, X-linked recessive, 3: 302802
- Charcot-Marie-Tooth disease, X-linked recessive, 4, with or without cerebellar ataxia: 310490
- Charcot-Marie-Tooth disease, X-linked recessive, 5: 311070
- Charcot-Marie-Tooth disease and deafness: 118300
- Charcot-Marie-Tooth disease with ptosis and parkinsonism: 118301
- Charcot-Marie-Tooth peroneal muscular atrophy, X-linked, with aplasia cutis congenita: 302803
- Charcot-Marie-Tooth peroneal muscular atrophy and Friedreich ataxia, combined: 302900
- Ehlers-Danlos syndrome, arthrochalasia type, 1: 130060
- Ehlers-Danlos syndrome, arthrochalasia type, 2: 617821
- Ehlers-Danlos syndrome, autosomal dominant, Type Unspecified: 130090
- Ehlers-Danlos syndrome, Beasley-Cohen type: 608763
- Ehlers-Danlos syndrome, cardiac valvular type: 225320
- Ehlers-Danlos syndrome, classic-like: 606408
- Ehlers-Danlos syndrome, classic-like, 2: 618000
- Ehlers-Danlos syndrome, classic type, 1: 130000
- Ehlers-Danlos syndrome, classic type, 2: 130010
- Ehlers-Danlos syndrome, dermatosparaxis type: 225410
- Ehlers-Danlos syndrome, hypermobility type: 130020
- Ehlers-Danlos syndrome, kyphoscloliotic type, 1: 225400
- Ehlers-Danlos syndrome, kyphoscoliotic type, 2: 614557
- Ehlers-Danlos syndrome, musculocontractural type, 1: 601776
- Ehlers-Danlos syndrome, musculocontractural type, 2: 615539
- Ehlers-Danlos syndrome, periodontal type, 1: 130080
- Ehlers-Danlos syndrome, periodontal type, 2: 617174
- Ehlers-Danlos syndrome, spondylodysplastic type, 1: 130070
- Ehlers-Danlos syndrome, spondylodysplastic type, 2: 615349
- Ehlers-Danlos syndrome, spondylodysplastic type, 3: 612350
- Ehlers-Danlos syndrome, vascular type: 130050
- Ehlers-Danlos syndrome with platelet dysfunction from fibronectin abnormality: 225310neuropathy, hereditary, with liability to pressure palsies (HNPP): 162500
- Refsum disease, classic: 266500
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Neuroimmunology
Chronic inflammatory demyelinating polyradiculoneuropathy
Sep. 07, 2024
-
Peripheral Neuropathies
Amyotrophic lateral sclerosis
Sep. 04, 2024
-
Peripheral Neuropathies
Amiodarone neuropathy
Sep. 04, 2024
-
Neuroimmunology
Autoimmune autonomic neuropathy
Aug. 31, 2024
-
Neurogenetic Disorders
Leukodystrophies
Aug. 25, 2024
-
Peripheral Neuropathies
Neuroacanthocytosis
Aug. 22, 2024
-
General Neurology
Peripheral nerve injuries
Aug. 19, 2024